Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab in metastatic castration-resistant prostate cancer
NCT02985957Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of nivolumab in prostate cancer (PCa) (7 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Objective Response Rate at 61 months and Radiographic Progression-Free Survival at 61 months. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02985957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985957.